The European Commission has authorized the use of Fruzaqla as a monotherapy for previously treated adult patients with metastatic colorectal cancer.
; Takeda) as a monotherapy for the treatment of adult patients with metastatic colorectal cancer . The approval is for those who have been previously treated with available standard therapies — including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti–vascular endothelial growth factor agents, and anti–epidermal growth factor receptor agents — and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib.
Median overall survival was 7.4 months in the treatment group compared with 4.8 months in the placebo group.
Metastatic CRC Mcrc Metastatic Colorectal Cancer (Mcrc) Colorectal Cancer Screening Colon Cancer Screening Vegf Inhibitor Vascular Endothelial Growth Factor Inhibitor Drug/Treatment Safety Drug Safety Treatment Safety Drug Development Drug Discovery Drug Pipeline Drug Development Pipeline Drug Legislation Drug Registries Drug Registry Drug Regulation
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
India approves $9-billion port to boost trade with EuropeIndia approves $9-billion port to boost trade with Europe
Read more »
From Europe, for Europe: Volkswagen Group Launches Project for €20,000 All-Electric EVFor Europe From Europe an all electric EV for 20000 EUR from the VW group entry level mobility from the respected manufacturer
Read more »
Chemo May Benefit Some Older Patients With Metastatic Pancreatic CancerBetter tools are needed to identify vulnerable older patients with metastatic pancreatic cancer who can undergo chemotherapy safely, experts said after finding that some can experience a benefit.
Read more »
Debulking Does Not Improve Survival in Multiorgan Metastatic CRCInvestigators found that tumor debulking in multiorgan metastatic colorectal cancer will not extend a patient's life.
Read more »
T-DXd Moves Toward the Front Line for HER2-Low Metastatic BCT-DXd, a targeted drug, extends progression-free survival by 5 months in patients with HER2-low metastatic breast cancer, outperforming chemotherapy as a first-line treatment.
Read more »
Swimming microrobots deliver cancer-fighting drugs to metastatic lung tumors in miceEngineers at the University of California San Diego have developed microscopic robots, known as microrobots, capable of swimming through the lungs to deliver cancer-fighting medication directly to metastatic tumors.
Read more »